Merck announced data from its Phase 3 study of its investigational sublingual grass (Phleum Pratense) allergy immunotherapy tablet (AIT) for the prevention of grass pollen allergy. The randomized, placebo-controlled study investigated the efficacy of AIT versus placebo in 345 children 5–17 years of age for the treatment of allergic rhinoconjunctivitis caused by pollen from Timothy grass. The primary efficacy endpoint was the total combined score, comprised of total daily symptom score and total daily medication score. Study data showed that treatment with AIT resulted in a 26% greater improvement in the total combined score compared to patients receiving placebo (p=0.001).
AIT is an investigational, dissolvable oral tablet that is designed to prevent allergy symptoms by inducing a protective immune response against allergies, thereby treating the underlying cause of the disease. Merck is investigating AIT for the treatment of grass pollen allergic rhinoconjunctivitis in both children and adults.
For more information call (800) 672-6372 or visit www.merck.com.